new
   Indications for Rasagiline (Azilect)
502
Nov 13, 2025

Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor. Since its approval by the U.S. FDA in 2006, it has become an important treatment option for Parkinson's disease. Its precise indication positioning, standardized dosage form design, and standardized storage requirements constitute the core elements of clinical medication use.

Indications for Rasagiline (Azilect)

Core Therapeutic Area

Rasagiline is clearly indicated for the treatment of Parkinson's disease (PD), covering disease management across different stages from early to advanced.

The medication can be used as monotherapy or a key component of combination therapy regimens.

Clinical Application Scenarios

Monotherapy: For patients with early-stage Parkinson's disease who have not received levodopa treatment.

Combination therapy: Used as an adjunct to levodopa to improve motor fluctuation symptoms.

Special populations: Can be used in combination with other anti-Parkinsonian medications such as dopamine agonists.

Specifications and Properties of Rasagiline (Azilect)

0.5 mg Tablets

White to off-white, round, flat tablets with beveled edges. One side is imprinted with "GIL 0.5", and the other side is a smooth surface.

1 mg Tablets

White to off-white, round, flat tablets with beveled edges. One side is imprinted with "GIL 1", and the other side remains smooth.

Both dosage forms use the same excipient formula: mannitol, starch, pregelatinized starch, colloidal silicon dioxide, stearic acid, and talc, ensuring drug stability and bioavailability.

Storage Methods for Rasagiline (Azilect)

Temperature Control Standards

The medication should be stored at 25°C (77°F), with short-term fluctuations allowed within the range of 15°C to 30°C (59°F to 86°F).

Packaging and Environmental Requirements

Packaging specifications: Supplied in bottles containing 30 tablets.

Environmental protection: Avoid exposure to direct sunlight, humid environments, and contact with heat sources.

Safety Precautions

Immediately seal the bottle cap after each use.

Store in a safe location out of the reach of children.

Avoid storing together with strong oxidants, acids, or alkalis.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
RELATED ARTICLES
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)

Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with...

Thursday, December 18th, 2025, 11:58
What Are the Indications for Capmatinib (Tabrecta)?

Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small...

Thursday, December 18th, 2025, 11:56
What Are the Purchase Channels for Capmatinib (Tabrecta)?

Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients...

Thursday, December 18th, 2025, 11:51
Adverse Reactions of Ivosidenib (Tibsovo)

Ivosidenib (Tibsovo) is an isocitrate dehydrogenase 1 (IDH1) inhibitor, primarily indicated for the treatment of...

Thursday, December 18th, 2025, 11:48
RELATED MEDICATIONS
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved